CVS Health (CVS) stock is lower in Tuesday's session on news the pharmacy chain's board of directors is conducting a strategic review of its business, according to media reports.
CVS has hired bankers to assist in exploring options, including the potential separation of its retail and insurance units into two publicly traded companies, people familiar with the matter told Reuters. The discussions are still in the early stages and no plans have been finalized.
A CVS spokesperson declined to comment on the report, but did tell Reuters the following:
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"CVS's management team and Board of Directors are continually exploring ways to create shareholder value," the spokesperson said. "We remain focused on driving performance and delivering high-quality healthcare products and services enabled by our unmatched scale and integrated model."
The report comes as CVS faces pressure from activist investor Glenview Capital. The hedge fund recently took a sizable stake in the healthcare stock and met with CVS executives to propose changes to improve its operations, according to The Wall Street Journal.
Is CVS Health stock a buy, sell or hold?
CVS Health's troubles haven't been solely on the fundamental side. Indeed, shares have underperformed on the price charts, too, down 18% on a total return basis (price change plus dividends) so far this year vs the S&P 500's 22% gain. Still, Wall Street remains bullish on the large-cap stock.
According to S&P Global Market Intelligence, the consensus analyst target price for CVS stock is $67.14, representing implied upside of more than 8% to current levels. Additionally, the consensus recommendation is Buy.
Financial services firm BofA Securities is one of those with a Buy rating on CVS stock, along with a $77 price target.
"CVS' reported decision to pursue a strategic review would not be particularly surprising given the company's recent execution issues," says BofA Securities analyst Allen Lutz, who adds that he has mixed feelings about a potential breakup.
While it could reasonable in a normal environment "to assume that the health plan Aetna could obtain a higher earnings multiple as a standalone business," the insurance provider's underperformance in 2024 "is the main driver of CVS' weak share price, and it is unclear how much investors would reward that business as a standalone entity, especially on current year or next year's earnings."
Lutz believes a stabilization in Aetna's earnings could "generate substantial shareholder value" and "significant upside potential."
Related Content
-
Striking Gold (or Gas): A Financial Pro Unpacks the Nuances of Energy InvestingInvesting in the energy industry, particularly oil and gas, involves understanding the facts about how projects generate returns through cash flow and long-term asset building, while also being aware of the risks.
-
Escaping the New Golden Handcuffs: A Financial Expert Has a Plan for Today's ExecutivesFeeling stuck in your job? It could be your complicated compensation package, but it also could be where you live, your family or even how you view yourself.
-
Striking Gold (or Gas): A Financial Pro Unpacks the Nuances of Energy Investing
Investing in the energy industry, particularly oil and gas, involves understanding the facts about how projects generate returns through cash flow and long-term asset building, while also being aware of the risks.
-
Escaping the New Golden Handcuffs: A Financial Expert Has a Plan for Today's Executives
Feeling stuck in your job? It could be your complicated compensation package, but it also could be where you live, your family or even how you view yourself.
-
Stock Market Winners and Losers of the 'Big, Beautiful' BillDefense, manufacturing and tech should prosper, while health care and green energy stocks face hurdles.
-
I'm a Financial Planner: Here's How to Invest Like the Wealthy, Even if You Don't Have MillionsPrivate market investments, once exclusive to the ultra-wealthy and institutions, have become more accessible to individual investors, thanks to regulatory changes and new investment structures.
-
Four Ways a Massive Emergency Fund Can Hurt You More Than It HelpsSaving too much could mean you're missing opportunities to put your money to work. Redirect some of that money toward paying off debt, building retirement funds, fulfilling a dream or investing in higher-growth options.
-
With Buffett Retiring, Should You Invest in a Berkshire Copycat?Warren Buffett will step down at the end of this year. Should you explore one of a handful of Berkshire Hathaway clones or copycat funds?
-
I'm a Financial Planner: How to Dodge a Retirement Danger You May Not Have Heard AboutTiming is everything, and sequence of returns risk can mean the difference between a retirement nest egg that's overflowing … or empty.
-
Caring for Aging Parents: An Expert Guide to Easing the Financial and Emotional StrainEarly conversations, financial planning and understanding the progression of care needs can help to mitigate stress and protect family relationships.
